Mirit Horenshtein Hadar
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mirit Horenshtein Hadar
Mirit Horenshtein Hadar is recorded as CFO at Silexion Therapeutics Corp (SLXN). Silexion Therapeutics Corp reported in an 8-K filed August 21, 2024 that Mirit Horenshtein Hadar was appointed Chief Financial Officer, effective August 15, 2024. The proxy statement of Silexion Therapeutics Corp reports total compensation of $770,090 for Mirit Horenshtein Hadar in fiscal 2024, including a base salary of $233,532. Disclosed compensation is on record for 2 fiscal years.
“Effective as of the Closing, the Board appointed Ilan Hadar, Mirit Horenshtein Hadar, CPA, and Dr. Mitchell Shirvan to serve as Chief Executive Officer, Chief Financial Officer, and Chief Scientific and Development Officer, respectively.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Silexion Therapeutics Corp
Other people whose current roles at this company are on record from its filings.
- Ilan Hadar CEO, Chairman
- Amnon Peled Board Member
- Avner Lushi Board Member
- Dror Abramov Board Member
- Ilan Levin Board Member
- Ilan Shiloah Board Member
- Ruth Alon Board Member
- Shlomo Noy Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Silexion Therapeutics Corp (SLXN) | Chief Financial Officer (formerly EVP Finance of Silexion Israel) | $233,532 | $770,090 |
| 2023 | Silexion Therapeutics Corp (SLXN) | Chief Financial Officer (formerly EVP Finance of Silexion Israel) | $26,238 | $26,238 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.